1. Claudia Ortiz Lopez, PharmD Candidate Cone Health Family Medicine
News You Can Use…
Claudia Ortiz Lopez, PharmD Candidate
Rob Vincent, PharmD
Pete Koval, PharmD
Cone Health Family Medicine
March, 2017

2. FDA Approval Parsabiv® (etelcalcetide)
Class: calcium-sensing receptor agonist
For the treatment of secondary hyperparathyroidism in adults with CKD on hemodialysis
Dose: 2.5mg/0.5 ml, 5 mg/mL and 10mg/2mL for IV injection
ADE: hypocalcemia, muscle spasm, nausea, diarrhea, vomiting
Calcinomimetic or cacium-sensing receptor agonist?
The recommended starting dose is 5 mg administered by intravenous bolus injection three times per week at the end of hemodialysis treatment. (2.1)  The maintenance dose is individualized and determined by titration based on parathyroid hormone (PTH) and corrected serum calcium response. The dose range is 2.5 to 15 mg three times per week. (2.1)

3. FDA Approval Siliq® (brodalumab)
Class: human interleukin-17 receptor A antagonist
For the treatment of moderate to severe plaque psoriasis
Dose: 210 mg SQ at weeks 0, 1, 2, then 210 mg every 2 weeks
ADE: injection site reaction, neutropenia, fatigue, diarrhea, myalgia
Contraindicated if have chrons disease

4. FDA Approval Tirosint-SOL® (levothyroxine sodium oral solution)
Treatment of hypothyroidism
Place in therapy: alternative dosage form for those that cannot swallow, tube fed OR possibly children with hypothyroidism
Oral solution: 13, 25, 50, 75, 88, 100, 112, 125, 137, 150, 175, 200 mcg/mL
Should i also include AE? Hyperthyroidism

5. Seasonal Influenza Vaccine Effectiveness
CDC Flu Shot Effectiveness estimates:
= 48%
Past Years
= 47%
= 19%
= 52%
= 49%

6. New IDSA guidelines for Meningitis/Ventriculitis
For detecting and treating ventriculitis and meningitis occurring after invasive procedures
Described symptoms associated with infection following each procedure
Recommendations for preventing infection during surgery
I do not know what to write here

7. January P&T Approvals
Brovana (arformoterol) will now be replacing all Long Acting Beta Agonists
Dulera (mometasone furoate/formoterol) will now be substituting Symbicort and Advair
Brovana (arformoterol) and Incruse (umeclidinium) will now be substituting all Long Acting Beta Agonists and Inhaled Corticosteroids combination products
Automatically substitute arformoterol (Brovana®) nebulizer solution (15 mcg, one inhalation BID), for any dose of salmeterol (Serevent®), formoterol (Foradil®, Perforomist®), olodaterol (Striverdi®), or indacaterol (Arcapta®). Page
 Remove budesonide/formoterol (Symbicort®) from the formulary.  For budesonide/formoterol (Symbicort®) or fluticasone propionate/salmeterol (Advair®), automatically substitute mometasone furoate/formoterol (Dulera®). Other formulary agents are also available as alternatives.
 Add umeclidinium (Incruse®) to the formulary.  Allow automatic substitution of arformoterol (Brovana®) nebulizer (15 mcg BID) plus umeclidinium (Incruse®) inhaler (1 puff daily) for any order for vilanterol/umeclidinium (Anoro Ellipta®), olodaterol/tiotropium (Stiolto Respimat®), or formoterol/glycopyrrolate (Bevespi Aerosphere®) combination product.
Cone Health Pharmacy and Therapeutics Committee Meeting Minutes, January 18th, 2017

8. January P&T Approvals
Added Basaglar® insulin glargine U-100 to formulary
Considered for formulary due to availability in pen device and cost
Basaglar Kwikpen ® (#5) $ vs Lantus Solostar (#5) $343.60
Basaglar® has been shown to be noninferior to Lantus®
Cone Health Pharmacy and Therapeutics Committee Meeting Minutes, January 18th, 2017

9. February P&T Approvals
Maintain linagliptin (Tradjenta ®) as sole DPP4 inhibitor
Allow automatic substitution of linagliptin for:
Alogliptin (Nesina ®)
Saxaglipgin (Onglyza ®)
Sitagliptin (Januvia ®)
DPP4
Cone Health Pharmacy and Therapeutics Committee Meeting Minutes, February 15th, 2017

10. February P&T Action
Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab)
Monoclonal antibodies that regulate inflammation and immune responses
Not added to Cone Health formulary due to lack of significant cost advantage
Crohn’s disease, pediatric Crohn’s disease in patients 6 years or older, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis
Should I include not added in the title = as that is the main topic
Cone Health Pharmacy and Therapeutics Committee Meeting Minutes, February 15th, 2017